Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
P/S ratio for Journey Medical Corporation (DERM)
P/S ratio as of 2023: 1.33
According to Journey Medical Corporation's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.33. At the end of 2022 the company had a P/S ratio of 0.46.
P/S ratio history for Journey Medical Corporation from 2014 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 1.33 |
| 2022 | 0.46 |
| 2021 | 1.48 |
| 2020 | 3.55 |
| 2019 | 4.53 |
| 2018 | 9.42 |
| 2017 | 84.86 |
| 2016 | 13.90 |
| 2015 | 34.78 |
| 2014 | 8.36 |